Radiopharmaceuticals for the Nuclear Medicine Department

This tender for radiopharmaceutical preparations is generally well-structured with accessible documents but lacks explicit evaluation criteria and sustainability considerations, impacting clarity and sustainability scores.

The tender adheres to open procedure requirements and proper CPV classification. While deadlines are provided, the overall clarity of the procedure is slightly hampered by missing evaluation criteria. No disputes are noted, suggesting a degree of regulatory compliance.

The tender title and description are clear, and most required documents are attached. However, the absence of specified evaluation criteria and the AI-extracted requirements section being blank significantly detract from overall clarity for potential bidders.

Basic information like title, reference, organization, and CPV code is present. Contract duration is specified. However, the estimated value is not disclosed, and the content of several attached documents remains unextracted, raising questions about completeness.

The tender is conducted via e-procurement and is divided into parts, promoting accessibility. All documents appear to be available, and there are no obvious indicators of requirements tailored to specific companies. The value is not disclosed, which is a minor concern.

The tender utilizes e-procurement, which is a positive. However, the actual contract start date is missing, and while the duration is 24 months, specific financing information beyond the value being undisclosed is absent. The AI-extracted requirements are not detailed.

Key fields such as title, reference, organization, and deadlines are populated. The tender is active, and no disputes or suspensions are recorded. Dates appear logically sequenced.

There is no mention of green procurement, social aspects, or innovation within the tender details. The tender is EU-funded, but specific sustainability objectives are not articulated.